ClinicalTrials.gov
public full text
Public Domain
Filgrastim for Premature Ovarian Insufficiency
Filgrastim is a Granulocyte-Colony Stimulating factor (G-CSF). It is an FDA approved drug. Very small embryonic-like stem cells (VSELs) are found in the ovary. Animal studies showed that these cells are able to regenerate the affected ovary. Studies on mice have shown that Filgrastim result in recovery of oogenesis after chemotherapy-induced gonadal failure (in 2013, 2014, and 2015).
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Bone Marrow Transplantation to Promote Follicle Recruitment in Poor Ovarian Reserve#875046
- Immunomodulatory Therapy in Women With Autoimmune Premature Ovarian Insufficiency#907306
- Ovarian Stimulation: Inositol and Melatonin#908227
- Use of G-CSF for the Treatment of Unexplained Recurrent Miscarriage#891323
- Liraglutide Treatment in Obese Infertile PCOS Women#1075678
Record · ID 857519
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive